Fluoroquinolone-resistant Escherichia coli isolates which overexpressed acrB and had a substitution at amino acid 45 of AcrR were complemented with wild-type acrR. Complementation led to increased sensitivity to ciprofloxacin and to ethidium bromide, suggesting that mutation at amino acid 45 of AcrR contributes to ciprofloxacin resistance.
The AcrAB-TolC efflux system has been shown to contribute to the intrinsic antibiotic resistance of Escherichia coli, and overexpression of this system can lead to multiple-antibiotic resistance (6) . Consequently, the genetic mechanisms leading to overexpression of acrAB have been the focus of recent interest. Initially, in vitro experiments suggested that the global regulators, MarA, SoxS, and Rob, all of which can activate transcription of acrAB, may be the primary mechanism by which overexpression of acrAB is mediated (1) . However, analysis of highly antibiotic resistant clinical isolates of E. coli, Salmonella enterica serovar Typhimurium, and Klebsiella pneumoniae by ourselves and others (7, 8, 9, 10, 11) have identified mutations within AcrR, the repressor of AcrAB (5) at a higher frequency than mutations within the mar, sox, and rob loci. Previously, we identified a number of ciprofloxacin-resistant mutants that overexpressed acrB from disparate locations and sources (animal isolates from the United Kingdom and human isolates from Argentina and Spain) which carried a cysteine replacing an arginine at amino acid 45 of AcrR (11) . While other workers have reported mutations throughout AcrR, the recurring mutation at position 45 in our isolates suggested that this mutation was particularly important. The fact that this mutation was detected among unrelated isolates from animals and humans from three geographically distant countries indicated that it is likely that this mutation can arise spontaneously in E. coli with diverse genetic backgrounds. Analysis of the structure of AcrR indicated that amino acid 45 lies within the middle of a putative helix-turn-helix DNA binding motif. Alignment of other AcrR homologues indicated that the arginine at position 45 is highly conserved, further evidence that mutation here will lead to loss of repressive function.
The aim of this study was to determine whether the mutation at amino acid 45 of AcrR observed in the isolates characterized previously was responsible for the elevated expression of AcrAB observed in these strains.
All the strains used in this study are listed in the table, strains I87, I88, I89, I237, I238, and I239 all carry the substitution of arginine with cysteine at amino acid 45 of AcrR and all carry a leucine replacing a serine at amino acid 83 of GyrA. Strains AG100 and AG102 are a wild-type E. coli K-12 strain and a marR1 derivative strain, respectively, which were used as controls (4) . Bacteria were cultured on Luria-Bertani agar and in Luria-Bertani broth. All chemicals were obtained from Sigma Aldrich Ltd. (Poole, United Kingdom). Ciprofloxacin was a kind gift of Bayer AG (Wuppertal, Germany).
The plasmid pAT was constructed for complementation experiments. Wild-type acrR was amplified from AG100 (using forward [5Ј GAACCTGAAGAACGACCTGA 3Ј] and reverse [5Ј CATCAGAACGACCGCACGAG 3Ј] primers) and, after verification by sequencing, cloned into pGEM-T Easy (Promega, Southampton, United Kingdom) to create pAT. pAT was electroporated into all the isolates with the substitution at amino acid 45.
The MIC of ciprofloxacin and ethidium bromide for each strain was determined by using the agar dilution method according to the guidelines of the British Society for Antimicrobial Chemotherapy by use of Iso-Sensitest agar (2) .
Expression of acrB and acrR was determined using comparative reverse transcription-PCR (3). RNA was prepared by using the RNAce spin cell mini kit (Bioline, London, United Kingdom) before being reverse transcribed into cDNA by using Superscript III (Invitrogen, Paisley, United Kingdom). Serial dilutions of cDNA were used as templates in PCRs for amplification of acrR, acrB, and 16S rRNA. The resulting amplimers were quantified by using a WAVE dHPLC instrument (Transgenomic, Crewe, United Kingdom) and Navigator software (Transgenomic, Crewe, United Kingdom). Expression of each gene was compared in early and late growth phase, in the presence and absence of pAT.
The MICs of each strain in the presence and absence of pAT are shown in Table 1 . The presence of pAT led to a two-to fourfold increase in sensitivity to ciprofloxacin for all the test strains and increased susceptibility to ethidium bromide for 3/6 test isolates. Transformation of AG100 with pAT alone caused no change in susceptibility to ciprofloxacin or ethidium bro-mide, indicating that the plasmid itself had no effect on susceptibility to these agents. Figure 1 shows the expression of acrB and acrR in early and late logarithmic growth phase. The addition of pAT led to clear changes in the expression levels of acrR and acrB ( Fig. 1A  and B , respectively). Increased acrR expression in the presence of pAT was observed for 5/6 strains at early logarithmic growth and for 4/6 strains at late logarithmic growth. In contrast, the addition of pAT led to a decrease in the expression of acrB for all strains at both growth phases investigated. These data suggest that the addition of pAT increases the amount of acrR expressed by the cell and that expression of wild-type acrR from the pAT vector leads to a reduction of acrB expression, presumably as a result of restoration of repressive activity.
The results presented here suggest that mutation at amino acid 45 of AcrR contributes to resistance to ciprofloxacin in conjunction with substitutions in GyrA as shown by the increased sensitivity to ciprofloxacin observed upon the addition of pAT to the ciprofloxacin-resistant strains. The mechanism of this is presumably by restoration of the repressive function of wild-type AcrR. These data suggest that mutation at amino acid 45 is important as a contributor to antibiotic resistance, and the detection of this mutation among diverse isolates from animals and humans from divergent geographical locations indicates that it may be of particular importance. However, the relative frequency of the occurrence of this mutation is unknown, and more isolates need to be examined to determine whether this mutation is a significant contributor to multipleantibiotic resistance in E. coli. Interestingly, although our laboratory has been successful in introducing a number of mutations into efflux-associated genes in various Enterobacteriaceae in recent years, attempts to artificially engineer this substitution in wild-type K-12 laboratory strains of E. coli by using the pKNOCK family of suicide vectors have not been successful to date. It is possible that attenuated laboratory strains are not amenable to this mutation being present or that specific selective conditions which we have been unable to recreate in the laboratory are required to select mutants carrying the substitution of arginine to cysteine in AcrR. Further characterization of the role of mutations within AcrR as a contributor to antibiotic resistance in conjunction with different topoisomerase genotypes is required to further define the role of this gene in resistance. 
